News | June 06, 2022
Proxygen and Merck collaborates to develop molecular glue degraders
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
The information center has been established with the aim of providing Fortis Healthcare’s world-class healthcare services accessible to the people of Tirupati.
RH Capital, a leading women's health venture capital fund, announced three new investments to improve health outcomes for women in the US.
Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
This agreement is in addition to the $92 million filling line expansion announced in November 2021
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Motrin Oral Suspension, 100 mg/5 mL, of McNeil Consumer Healthcare (McNeil)
Dr Jitendra Singh said, the Biotech Park would act as a hub for incubation of new ideas
Subscribe To Our Newsletter & Stay Updated
